再生医療の世界市場予測（～2021年）：細胞治療、組織工学、免疫治療、遺伝子治療...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 MARKET SCOPE 12
1.3.1 MARKETS COVERED 13
1.3.2 YEARS CONSIDERED FOR THE STUDY 13
1.4 CURRENCY 13
1.5 LIMITATIONS 14
1.6 STAKEHOLDERS 14

2 RESEARCH METHODOLOGY 15
2.1 MARKET SIZE ESTIMATION 16
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 19
2.3 MARKET SHARE ESTIMATION 20
2.3.1 KEY DATA FROM SECONDARY SOURCES 20
2.3.2 KEY DATA FROM PRIMARY SOURCES 21
2.3.3 ASSUMPTIONS FOR THE STUDY 21

3 EXECUTIVE SUMMARY 22

4 PREMIUM INSIGHTS 25
4.1 REGENERATIVE MEDICINE: MARKET OVERVIEW 25
4.2 GEOGRAPHIC ANALYSIS: REGENERATIVE MEDICINE MARKET, BY THERAPY, 2016 26
4.3 GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET 27

5 MARKET OVERVIEW 28
5.1 INTRODUCTION 29
5.2 MARKET DYNAMICS 29
5.3 DRIVERS 30
5.3.1 GOVERNMENT & PRIVATE FUNDING TO SUPPORT THE DEVELOPMENT OF REGENERATIVE MEDICINE 30
5.3.2 RISING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS 30
5.3.3 INCREASE IN GLOBAL HEALTHCARE EXPENDITURE 31
5.3.4 RAPID GROWTH IN THE AGING POPULATION 31
5.3.5 INCREASE IN CORPORATE PARTNERSHIPS TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF REGENERATIVE MEDICINE 32
 
5.4 RESTRAINTS 33
5.4.1 ETHICAL CONCERNS WITH THE USE OF EMBRYONIC STEM CELL FOR R&D 33
5.4.2 LACK OF CLEAR REGULATORY GUIDELINES 33
5.5 OPPORTUNITIES 34
5.5.1 RISING DEMAND FOR ORGAN TRANSPLANTATION 34
5.5.2 STRONG PRODUCT PIPELINE 34

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT 36
6.1 INTRODUCTION 37
6.2 CELL-BASED PRODUCTS 39
6.2.1 ALLOGENEIC PRODUCTS 41
6.2.2 AUTOLOGOUS PRODUCTS 42
6.3 ACELLULAR PRODUCTS 43

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY 44
7.1 INTRODUCTION 45
7.2 CELL THERAPY 46
7.3 TISSUE ENGINEERING 48
7.4 IMMUNOTHERAPY 49
7.5 GENE THERAPY 50

8 REGENERATIVE MEDICINE MARKET, BY APPLICATION 52
8.1 INTRODUCTION 53
8.2 ORTHOPEDIC & MUSCULOSKELETAL DISORDERS 55
8.3 DERMATOLOGY 56
8.4 CARDIOLOGY 57
8.5 CENTRAL NERVOUS SYSTEM DISEASES 57
8.6 ONCOLOGY 59
8.7 DIABETES 60
8.8 OTHER APPLICATIONS 61

9 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION 63
9.1 INTRODUCTION 64
9.2 NORTH AMERICA 65
9.2.1 U.S. 69
9.2.2 CANADA 72
 
9.3 EUROPE 75
9.3.1 GERMANY 79
9.3.2 U.K. 82
9.3.3 FRANCE 84
9.3.4 ITALY 86
9.3.5 SPAIN 88
9.3.6 REST OF EUROPE (ROE) 91
9.4 ASIA-PACIFIC 93
9.5 REST OF THE WORLD (ROW) 98

10 COMPETITIVE LANDSCAPE 102
10.1 OVERVIEW 102
10.2 MARKET RANKING 103
10.3 COMPETITIVE SITUATION AND TRENDS 105
10.3.1 ACQUISITIONS 106
10.3.2 PARTNERSHIPS 107
10.3.3 REGULATORY APPROVALS 108
10.3.4 NEW PRODUCT DEVELOPMENTS 109
10.3.5 OTHERS 110

11 COMPANY PROFILES 111
(Overview, Financial*, Products & Services, Strategy, and Developments)
11.1 ACELITY L.P. INC. (KCI LICENSING) 111
11.2 NUVASIVE, INC. 113
11.3 VERICEL CORPORATION 115
11.4 OSIRIS THERAPEUTICS, INC. 117
11.5 INTEGRA LIFESCIENCES CORPORATION 119
11.6 STRYKER CORPORATION 122
11.7 MEDTRONIC PLC 124
11.8 COOK BIOTECH INCORPORATED 126
11.9 ORGANOGENESIS INC. 128
11.10 JAPAN TISSUE ENGINEERING CO., LTD. (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 129
*Details might not be captured in case of unlisted companies.

12 APPENDIX 130
12.1 INSIGHTS FROM INDUSTRY EXPERTS 130
12.2 DISCUSSION GUIDE 131
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 133
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 135
12.5 AVAILABLE CUSTOMIZATIONS 135
12.6 RELATED REPORTS 136
12.7 AUTHOR DETAILS 137